Leora Horn
As head of Clinical Development, Late Oncology I am accountable for the development and resourcing for the physicians and scientists who are currently responsible for studies in late oncology from Phase I signal seeking to Ph3 registrational trials spanning multiple Oncology indications.
Additionally as a Clinical Strategy Head, I lead the company’s global research and development in lung cancer, a disease that despite many gains in recent years, remains the most common cause of cancer related mortality around the world. In my role, I partner with teams from across AstraZeneca Oncology to rapidly progress our research and deliver on our commitment to eliminate cancer as a cause of death.
Prior to joining AstraZeneca I earned a medical degree from University of Toronto, where I trained in internal medicine and medical oncology, and also received a Masters of Science in Pharmacology. I completed a Thoracic Fellowship at Vanderbilt University where I went on to lead the lung cancer program for over a decade. Following my passion for people development, I completed a Masters in Health Professions Education from the University of Illinois, and developed faculty development programs for clinician educators and researchers.
I have served as principal investigator on several national and global lung cancer trials for immunotherapies, targeted therapies and novel treatments across early and late development, and have published more than 175 papers and book chapters. I am also an active member and served on the scientific committees of the American Society of Clinical Oncology, the European Society of Medical Oncology, the International Association for the Study of Lung Cancer, and the Royal College of Physicians and Surgeons of Canada.
It is energizing to be part of AstraZeneca, working with brilliant teams at an inspiring pace, driven by a shared purpose, to bring new therapies to patients and eliminate cancer as a cause of death. We focus on learning, development and delivery of high-quality innovative studies to redefine cancer care. I’m excited about the work we’re doing to improve screening, identify novel populations and biomarkers as we deliver the next wave of treatments for patients with lung cancer.
CURRENT ROLE
2009-2020
2009-2015
2008-2009
Featured publications
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS. Lancet Oncol. 2015 Mar;16(3):257-65. doi: 10.1016/S1470-2045(15)70054-9.
Pembrolizumab for the treatment of non-small cell lung cancer.
Pembrolizumab for the treatment of non-small cell lung cancer. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L. N Engl J Med. 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824.
AZD9291 in EGFR inhibitor-resistant non-small cell lung cancer.
AZD9291 in EGFR inhibitor-resistant non-small cell lung cancer. Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M. N Engl J Med. 2015 Apr 30;372(18):1689-99. doi: 10.1056/NEJMoa1411817.
Nivolumab versus docetaxel in advanced nonsquamous non-small cell lung cancer.
Nivolumab versus docetaxel in advanced nonsquamous non-small cell lung cancer. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus docetaxel in advanced nonsquamous non-small cell lung cancer. New England Journal of Medicine 373 (17): 1627-39.
Nivolumab alone and nivolumab plus ipilimumab in recurrent small cell lung cancer (Checkmate 032) a multicenter, open label, phase 1/2 trial.
Nivolumab alone and nivolumab plus ipilimumab in recurrent small cell lung cancer (Checkmate 032) a multicenter, open label, phase 1/2 trial. Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, Jäger D, Pietanza MC, Le DT, de Braud F, Morse MA, Ascierto PA, Horn L, Amin A, Pillai RN, Evans J, Chau I, Bono P, Atmaca A, Sharma P, Harbison CT, Lin CS, Christensen O, Calvo E. Lancet Oncol. 2016 Jul;17(7):883-895. doi: 10.1016/S1470-2045(16)30098-5.
First-Line Nivolumab in Stage IV or Recurrent Non-Small Cell Lung cancer.
First-Line Nivolumab in Stage IV or Recurrent Non-Small Cell Lung cancer. Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR Jr, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA; N Engl J Med. 2017 Jun 22;376(25):2415-2426. doi: 10.1056/NEJMoa1613493.
Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.
Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL, Adjei AA, Leighl NB, Aisner SC, Rothman JM, Patel JD, Sborov MD, McDermott SR, Perez-Soler R, Traynor AM, Butts C, Evans T, Shafqat A, Chapman AE, Kasbari SS, Horn L, Ramalingam SS, Schiller JH; Lancet Oncol. 2017 Dec;18(12):1610-1623. doi: 10.1016/S1470-2045(17)30691-5.
Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK + lung cancer.
Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK + lung cancer. Horn L, Whisenant JG, Wakelee H, Reckamp KL, Qiao H, Leal TA, Du L, Hernandez J, Huang V, Blumenschein GR, Waqar SN, Patel SP, Nieva J, Oxnard GR, Sanborn RE, Shaffer T, Garg K, Holzhausen A, Harrow K, Liang C, Lim LP, Li M, Lovly CM. J Thorac Oncol. 2019 Nov;14(11):1901-1911. doi: 10.1016/j.jtho.2019.08.003.
COVID-19 in Patients With Thoracic Malignancies (TERAVOLT): First Results of an International, Registry-Based, Cohort Study
COVID-19 in Patients With Thoracic Malignancies (TERAVOLT): First Results of an International, Registry-Based, Cohort Study. Garassino MC, Whisenant JG, Huang LC, Trama A, Torri V, Agustoni F, Baena J, Banna G, Berardi R, Bettini AC, Bria E, Brighenti M, Cadranel J, De Toma A, Chini C, Cortellini A, Felip E, Finocchiaro G, Garrido P, Genova C, Giusti R, Gregorc V, Grossi F, Grosso F, Intagliata S, La Verde N, Liu SV, Mazieres J, Mercadante E, Michielin O, Minuti G, Moro-Sibilot D, Pasello G, Passaro A, Scotti V, Solli P, Stroppa E, Tiseo M, Viscardi G, Voltolini L, Wu YL, Zai S, Pancaldi V, Dingemans AM, Van Meerbeeck J, Barlesi F, Wakelee H, Peters S, Horn L; Lancet Oncol. 2020 Jul;21(7):914-922. doi: 10.1016/S1470-2045(20)30314-4.
http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2820%2930314-4/fulltext